Top Suppliers:I want be here



16037-91-5

16037-91-5 structure
16037-91-5 structure
  • Name: Stibogluconate sodium
  • Chemical Name: sodium stibogluconate
  • CAS Number: 16037-91-5
  • Molecular Formula: C12H38Na3O26Sb2
  • Molecular Weight: 910.90
  • Catalog: API Antiparasitic drug Resistance to filariasis and anti-leishmaniasis
  • Create Date: 2018-06-10 21:39:12
  • Modify Date: 2024-01-11 10:39:59
  • Stibogluconate sodium is a potent inhibitor of protein tyrosine phosphatase. Stibogluconate sodium inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.

Name sodium stibogluconate
Synonyms 1,3,7,9-Tetraoxa-2,8-distibacyclododecane-4,10-dicarboxylic acid, 6,12-bis[(1R)-1,2-dihydroxyethyl]-2,5,8,11-tetrahydroxy-, 2,8-dioxide, sodium salt, (4R,5R,6R,10R,11R,12R)-, hydrate (1:3:9)
stibanose
stibinol
ANTIMONY SODIUM GLUCONATE
MFCD06795860
solustin
SSG
NASB
stibatin
stibanate
myostibin
pentostam
Sodium (4R,5R,6R,10R,11R,12R)-6,12-bis[(1R)-1,2-dihydroxyethyl]-2,5,11-trihydroxy-8-oxido-1,3,7,9-tetraoxa-2,8-distibacyclododecane-4,10-dicarboxylate 2,8-dioxide hydrate (3:1:9)
NASBV
Stibogluconate (sodium)
Description Stibogluconate sodium is a potent inhibitor of protein tyrosine phosphatase. Stibogluconate sodium inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.
Related Catalog
Target

Phosphatase[1]

In Vitro Stibogluconate sodium inhibits 99% of SHP-1 activity at 10 μg/mL, a therapeutic concentration of the drug for leishmaniasis. Similar degrees of inhibition of SHP-2 and PTP1B required 100 μg/mL Stibogluconate sodium. The inhibition of cellular PTPases by the Stibogluconate sodium is suggested by its rapid induction of tyrosine phosphorylation of cellular proteins in Baf3 cells and its augmentation of IL-3-induced Janus family kinase 2/Stat5 tyrosine phosphorylation and proliferation of Baf3 cells. The augmentation of the opposite effects of GM-CSF and IFN-α on TF-1 cell growth by Stibogluconate sodium indicate its broad activities in the signaling of various cytokines[1].
In Vivo Stibogluconate sodium induces 61% growth inhibition of Renca tumors in BALB/c mice coincident with an increase (2-fold) in tumor-infiltrating macrophages. A combination of Stibogluconate sodium and IL-2 is more effective in inhibiting tumor growth (91%) and inducing tumor-infiltrating (4-fold), whereas IL-2 alone has little effect[2].
Cell Assay Human myeloid cell line TF-1 is maintained in RPMI 1640 supplemented with 10% FCS and 40 ng/mL recombinant human GM-CSF. For cell proliferation assays, cells are washed in 10% FCS medium twice, resuspended in 10% FCS medium, incubated at 37°C for 16 h, and then cultured at 37°C in 10% FCS medium containing various amounts of cytokines, sodium stibogluconate, or potassium antimonyl tartrate for 3-6 days. The cell numbers in proliferation assays are determined by an MTT assay or by microscopic cell counting[1].
Animal Admin BALB/c and athymic nude BALB/c mice are inoculated (s.c.) at the flanks with Renca cells (106 cells/site). Four days after inoculation, the mice are subjected to no treatment (control) or treatment with IL-2 (105 IU/day for 5 days i.p.), Stibogluconate sodium (12 mg/day i.m. at hip regions), or the combination of the two agents for 2 wk. Tumor volume is measured during the study period and calculated using the formula for a prolate spheroid[2].
References

[1]. Pathak MK, et al. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol. 2001 Sep 15;167(6):3391-7.

[2]. Fan K et al. Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages. J Immunol. 2005 Nov 15;175(10):7003-8.

Boiling Point 673.6ºC at 760mmHg
Molecular Formula C12H38Na3O26Sb2
Molecular Weight 910.90
Flash Point 375.2ºC
PSA 399.06000
Appearance solid | pale yellow
Vapour Pressure 4.95E-21mmHg at 25°C
Water Solubility H2O: 1 mg/mL at ~75 °C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
CC7930000
CAS REGISTRY NUMBER :
16037-91-5
LAST UPDATED :
199712
DATA ITEMS CITED :
31
MOLECULAR FORMULA :
C12-H20-O17-Sb2.3Na.9H2-O
MOLECULAR WEIGHT :
1048.91

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
33 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CLDND* Compilation of LD50 Values of New Drugs. (J.R. MacDougal, Dept. of National Health and Welfare, Food and Drug Divisions, 35 John St., Ottawa, Ont., Canada)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7747 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IJPAAO Indian Journal of Pharmacy. (Bombay, India) V.1-40(1), 1939-78. For publisher information, see IJSIDW. Volume(issue)/page/year: 11,155,1949
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1625 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 18,451,1993 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
77537 mg/kg/30D-I
REFERENCE :
HETOEA Human & Experimental Toxicology. (Macmillan Press Ltd., Brunel Road, Houndmills, Basingstoke, Hampshire, RG21 2XS, UK) V.9- 1990- Volume(issue)/page/year: 11,283,1992 *** REVIEWS *** ACGIH TLV-TWA 0.5 mg(Sb)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 TOXICOLOGY REVIEW FAZMAE Fortschritte der Arzneimittelforschung. Progress in Drug Research. (Birkhauser Boston, Inc., c/o Springer-Verlag New York, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1959- Volume(issue)/page/year: 17,108,1973 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.5 mg(Sb)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,15,1971 OSHA PEL (Gen Indu):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1000,1994 OSHA PEL (Construc):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1926.55,1994 OSHA PEL (Shipyard):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1915.1000,1993 OSHA PEL (Fed Cont):8H TWA 0.5 mg(Sb)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 41,50-204.50,1994 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-AUSTRALIA:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-AUSTRIA:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-BELGIUM:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-DENMARK:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-FINLAND:.TWA (0.5 mg(Sb)/m3) JAN 1993 OEL-FRANCE:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-GERMANY:TWA 0.5 mg(Sb)/m3 (total dust) JAN 1993 OEL-HUNGARY:STEL 0.5 mg(Sb)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-RUSSIA:TWA 0.2 mg(Sb)/m3;STEL 0.5 mg(Sb)/m3 JAN 1993 OEL-SWEDEN:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-SWITZERLAND:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(Sb)/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ANTIMONY-air:10H TWA 0.5 mg(Sb)/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992
Hazard Codes Xn,N
Risk Phrases 20/22-51/53
Safety Phrases 61
RIDADR UN 3282
WGK Germany 3
RTECS CC7930000
Packaging Group III
Hazard Class 6.1(b)